Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem in Subjects With Fibromyalgia.

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem in Subjects With Fibromyalgia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium oxybate (Primary)
  • Indications Fibromyalgia
  • Focus Registrational; Therapeutic Use
  • Sponsors Jazz Pharmaceuticals Inc

    • Most Recent Events

    • 06 May 2010 Results presented at 29th Annual Scientific Meeting of the American Pain Society.
    • 14 Apr 2010 Results presented at 62nd Annual Meeting of the American Academy of Neurology 2010.
    • 16 Dec 2009 According to a Jazz Pharmaceuticals media release, a New Drug Application has been submitted to the US FDA based on results from this and another pivotal trial (trial profile 700020839).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top